Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations.

Biologics are effective treatments for patients with severe allergic disease. Impacts of delays in the prior authorization process on clinical outcomes has not been studied. The objective was to quantify the times for approval and filling of biologics, and whether patients were at risk of exacerbations during this time frame.